Prevalence and associated risk factors of non-alcoholic fatty liver disease in hospitalized patients

Journal of Gastrointestinal and Liver Diseases

Volumn 17, Issue 3, 2008, Pages 255-260

  Radu, Corina ^a   Grigorescu, Mircea ^a   Crisan, Dana ^a   Lupsor, Monica ^a   Constantin, Diana ^a   Dina, Liliana ^a  

^a IULIU HATIEGANU UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

Author keywords

Central obesity; Metabolic syndrome; Non alcoholic liver disease; Prevalence; Risk factor

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; AGED; ANTHROPOMETRY; ARTICLE; BIOCHEMISTRY; BODY MASS; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DIET RESTRICTION; DISEASE ASSOCIATION; ECHOGRAPHY; FEMALE; GLUCOSE BLOOD LEVEL; HOSPITAL PATIENT; HUMAN; HYPERTENSION; HYPERTRIGLYCERIDEMIA; INTERVIEW; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MEDICAL ASSESSMENT; MEDICAL RECORD REVIEW; METABOLIC SYNDROME X; NONALCOHOLIC FATTY LIVER; OBESITY; PREVALENCE; RISK FACTOR; ROMANIA; SYSTOLIC BLOOD PRESSURE; WAIST CIRCUMFERENCE;

EID: 54349090849     PISSN: 18418724     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Angulo P. GI epidemiology: nonalcoholic fatty liver disease. Aliment Pharmacol Ther 2007; 25: 883-889.
2. Adams LA, Angulo P, Lindor KD. Nonalcoholic fatty liver disease. CMAJ 2005; 172: 899-905.
3. The IDF consensus worldwide definition of the metabolic syndrome. 2005; available at: http://www.idf.org/webdata/docs/MetSyndrome_FINAL.pdf
4. Farrel GC. Non-alcoholic fatty liver and non-alcoholic steatohepatitis. In: Textbook of hepatology. From basic science to clinical practice. 3rd Edn, Oxford: Blackwell Publishing 2007, 1195-1207.
5. Björnsson E. The clinical aspects of non-alcoholic fatty livet disease. Minerva Gastroenterol Dietol 2008; 54: 7-18.
6. Palasciano G, Moschetta A, Palmieri VO, Grattagliano I, Iacobellis G, Portincasa P. Non-alcoholic fatty liver disease in the metabolic syndrome. Curr Pharm Des 2007; 13: 2193-2198.
7. Tarantino G, Saldalamacchia G, Conca P, Arena A. Non-alcoholic fatty liver disease: further expression of the metabolic syndrome. J Gastroenterol Hepatol 2007; 22: 293-303.
8. Falck-Ytter Y, Younossi ZM, Marchesini G, McCullough AJ. Clinical features and natural history of nonalcoholic steatosis syndromes. Semin Liver Dis 2001; 21: 17-26.
9. Clark JM, Diehl AM. Defining nonalcoholic fatty liver disease: implications for epidemiologic studies. Gastroenterology 2003; 124: 248-250.
10. Sheth SG, Chopra S. Nonalcoholic steatohepatitis. In: UpToDate 2008; version 16.1.
11. De Lusong MA, Labio E, Daez L, Gloria V. Non-alcoholic fatty liver disease in the Philippines: comparable with other nations? World J Gastroenterol 2008; 14: 913-917.
12. Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults - The Evidence Report. National Institutes of Health. Obes Res 1998; 6 Suppl 2: 51S-209S.
13. Nomura H, Kashiwagi S, Hayashi J, Kajiyama W, Tani S, Goto M. Prevalence of fatty liver in a general population of Okinawa, Japan. Jpn J Med 1988; 27: 142-149.
14. Lonardo A, Bellini M, Tartoni P, Tondelli E. The bright liver syndrome. Prevalence and determinants of a "bright" liver echopattern. Ital J Gastroenterol Hepatol 1997; 29: 351-356.
15. Bellentani S, Saccocio G, Masatti F, et al. Preavlence of and risk factors for hepatic steatosis in Northern Italy. Ann Intern Med 2000; 132:112-117.
16. Araújo LM, De Oliveira DA, Nunes DS. Liver and biliary ultrasonography in diabetic and non-diabetic obese women. Diabetes Metab 1998; 24: 458-462.
17. Omagari K, Kadokawa Y, Masuda J, et al. Fatty liver in non-alcoholic non-overweight Japanese adults: incidence and clinical characteristics. J Gastroenterol Hepatol 2002; 17: 1098-1105.
18. Patt CH, Yoo HY, Dibadj K, Flynn J, Thuluvath PJ. Prevalence of transaminase abnormalities in asymptomatic, healthy subjects participating in an executive health-screening program. Dig Dis Sci 2003; 48: 797-801.
19. Clark JM, Brancati FL, Diehl AM. Nonalcoholic fatty liver disease. Gastroenterology 2002; 122: 1649-1657.
20. Clark JM, Brancati FL, Diehl AM. The prevalence and etiology of elevated aminotransferase levels in the United States. Am J Gastroenterol 2003; 98: 960-967.
21. Ruhl CE, Everhart JE. Determinants of the association of overweight with elevated serum alanine aminotransferase activity in the United States. Gastroenterology 2003; 124: 71-79.
22. Chitturi S, Farrell GC, Hashimoto E, Saibara T, Lau GK, Sollano JD; Asia-Pacific Working Party on NAFLD. Non-alcoholic fatty liver disease in the Asia-Pacific region: definitions and overview of proposed guidelines. J Gastroenterol Hepatol 2007; 22: 778-787.
23. Saadeh S, Younossi ZM, Remer EM, et al. The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology 2002; 123: 745-750.
24. Loria P, Lonardo A, Bellentani S, Day CP, Marchesini G, Carulli N. Non-alcoholic fatty liver disease (NAFLD) and cardiovascular disease: an open question. Nutr Metab Cardiovasc Dis 2007; 17: 684-698.
25. Imhof A, Kratzer W, Boehm B, et al. Prevalence of non-alcoholic fatty liver and characteristics in overweight adolescents in the general population. Eur J Epidemiol 2007; 22: 889-897.
26. Shen L, Fan JG, Shao Y, et al. Prevalence of nonalcoholic fatty liver among administrative officers in Shanghai: an epidemiological survey. World J Gastroenterol 2003; 9: 1106-1110.
27. Grigorescu M, Radu C, Pascu O, et al. Etiological profile of chronic hepatitis and liver cirrhosis in Romania - a multicentre study. Rom J Gastroenterol 2001; 10: 199-204.
28. Mokdad AH, Ford ES, Bowman BA, et al. Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA 2003; 289: 76-79.
29. McCullough AJ. The epidemiology and risk factors of NASH. In: Fatty liver disease: NASH and related disorders. Oxford: Blackwell Publ 2005: 23-37.
30. Angulo P. NAFLD, obesity, and bariatric surgery. Gastroenterology 2006; 130: 1848-1852.
31. Stranges S, Dorn JM, Muti P, et al. Body fat distribution, relative weight, and liver enzyme levels: a population-based study. Hepatology 2004; 39: 754-763.
32. Huang HL, Lin WY, Lee LT, Wang HH, Lee WJ, Huang KC. Metabolic syndrome is related to nonalcoholic steatohepatitis in severely obese subjects. Obes Surg 2007; 17: 1457-1463.
33. Chu CJ, Lu RH, Wang SS, et al. Risk factors associated with non-alcoholic fatty liver disease in Chinese patients and the role of tumor necrosis factor-alpha. Hepatogastroenterology 2007; 54: 2099-2102
34. Omagari K, Kadokawa Y, Masuda J, et al. Fatty liver in non-alcoholic non-overweight Japanese adults: incidence and clinical characteristics. Gastroenterol Hepatol 2002; 17: 1098-1105.
35. International Diabetes Federation. Obesity. In: Diabetes Atlas. 2nd Ed, Brussels: 2003, 21-23; available at: www.idf.org/e-atlas.
36. Roman G. The metabolic syndrome. In: Therapeutic education in the metabolic syndrome]. Cluj-Napoca: Echinox Publ 2004, 91-128.
37. Marchesini G, Bugianesi E, Forlani G, et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 2003; 37: 917-923.
38. Karnikowski M, Córdova C, Oliveira RJ, Karnikowski MG, Nóbrega Ode T. Non-alcoholic fatty liver disease and metabolic syndrome in Brazilian middle-aged and older adults. Sao Paulo Med J 2007; 125: 333-337.
39. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-2497.
40. WHO consultation. Definition, diagnosis and classification of diabetes mellitus and its complications. Geneva: WHO, 1999, report No WHO/NCD/NCS/ 99.2.
41. Chan HL, de Silva HJ, Leung NW, Lim SG, Farrell GC; Asia-Pacific Working Party on NAFLD. How should we manage patients with non-alcoholic fatty liver disease in 2007? J Gastroenterol Hepatol 2007; 22: 801-808.
42. McAvoy NC; Ferguson JW, Campbell IW, Hayes PC. Non-alcoholic fatty liver disease: natural history, pathogenesis and treatment. Br J Diabetes Vasc Dis 2006; 6: 251-260.